24/7 Market News Snapshot 11 September, 2025 – Kazia Therapeutics Limited American Depositary Shares (NASDAQ:KZIA)

September 11, 2025

DENVER, Colo., 11 September, 2025 (www.247marketnews.com) – (NASDAQ:KZIA) are discussed in this article.
Kazia Therapeutics Limited (NASDAQ:KZIA), a leader in oncology-specific drug development, is experiencing a robust bullish trend in the market, with its stock trading at $11.645, a remarkable increase of 41.15% from the previous close of $8.250. This significant surge has generated considerable interest among investors, spurred by the company’s latest advancements and a trading volume exceeding 1.25 million shares. Analysts are closely monitoring this trajectory, optimistic about future price milestones as market confidence continues to grow.

In conjunction with its financial momentum, Kazia has announced compelling outcomes from a collaborative research initiative focused on paxalisib, an investigational PI3K-mTOR inhibitor. This innovative compound has shown promise in treating HER2-positive metastatic breast cancer (mBC), as detailed in a study led by Professor Sudha Rao. The research revealed statistically significant reductions in circulating tumor cells (CTCs) in patients diagnosed with Stage IV HER2-positive mBC. Notably, paxalisib’s efficacy was highlighted by its complete disruption of clusters of CTCs, a critical factor associated with aggressive disease progression.

Dr. John Friend, CEO of Kazia Therapeutics, emphasized the transformative potential of these findings in addressing unmet medical needs in HER2-positive breast cancer. The drug’s application extends beyond previous clinical focuses, marking an essential development in the treatment landscape. As the company progresses into a Phase 1b trial that explores paxalisib in conjunction with other therapies for advanced breast cancer, preliminary results reinforce its position as a promising contender in precision medicine.

Kazia Therapeutics plans to present these pivotal findings at a major global oncology conference in 2025, further underscoring its commitment to advancing innovative therapeutic options for patients battling challenging cancer types. This focus on targeted therapies aims to enhance treatment efficacy and provide tailored solutions in the landscape of cancer care.

Related news for (KZIA)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.